BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty biopharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced that it raised $2 million in Series A-2 financing. The funding enables the Company to complete a Phase 1, combined single and multiple rising dose clinical trial evaluating the safety and pharmacokinetics of EMB-001 in volunteers who smoke cigarettes but are otherwise healthy.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
